Published in Int J Mol Sci on November 06, 2013
Recombinant Laminins Drive the Differentiation and Self-Organization of hESC-Derived Hepatocytes. Stem Cell Reports (2015) 0.95
Modulating innate immunity improves hepatitis C virus infection and replication in stem cell-derived hepatocytes. Stem Cell Reports (2014) 0.89
New markers for tracking endoderm induction and hepatocyte differentiation from human pluripotent stem cells. Development (2015) 0.79
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 71.50
Embryonic stem cell lines derived from human blastocysts. Science (1998) 65.53
Direct conversion of fibroblasts to functional neurons by defined factors. Nature (2010) 18.76
Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature (2005) 17.47
Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell (2010) 15.58
Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov (2004) 15.57
Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol (2000) 12.41
Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med (2004) 10.91
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature (2011) 5.84
Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med (2000) 5.83
Direct conversion of human fibroblasts to multilineage blood progenitors. Nature (2010) 5.35
Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature (2011) 5.28
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife (2012) 5.18
Alcoholic liver disease. Hepatology (2010) 5.04
Cytochrome p450 and chemical toxicology. Chem Res Toxicol (2007) 4.49
Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology (2008) 3.99
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest (2010) 3.91
Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology (2010) 3.36
Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. Gastroenterology (2012) 3.34
Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci U S A (2008) 2.99
Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol (2001) 2.95
The future of drug development: advancing clinical trial design. Nat Rev Drug Discov (2009) 2.68
In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol (1998) 2.45
Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells (2008) 2.29
Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 2.20
Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Rev (2010) 1.98
Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 1.78
Generation of functional hepatocyte-like cells from human pluripotent stem cells in a scalable suspension culture. Stem Cells Dev (2013) 1.63
Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism. Stem Cell Res (2010) 1.62
Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep (2006) 1.55
Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells in vitro and in vivo. Stem Cells (2007) 1.54
Hepatitis delta virus. Virology (2006) 1.45
Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol (1999) 1.43
Progress and future challenges in stem cell-derived liver technologies. Am J Physiol Gastrointest Liver Physiol (2009) 1.32
Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab (2008) 1.30
Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog (2012) 1.29
Reprogramming fibroblasts into bipotential hepatic stem cells by defined factors. Cell Stem Cell (2013) 1.28
Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl Med (2013) 1.27
Direct differentiation of human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. Cloning Stem Cells (2007) 1.25
Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab (2004) 1.22
Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum Mol Genet (2011) 1.20
Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J Hepatol (2012) 1.11
Pluripotent stem cell-derived hepatocytes: potential and challenges in pharmacology. Annu Rev Pharmacol Toxicol (2013) 1.10
Acetaldehyde as an underestimated risk factor for cancer development: role of genetics in ethanol metabolism. Genes Nutr (2009) 1.09
The comparison between conditioned media and serum-free media in human embryonic stem cell culture and differentiation. Cell Reprogram (2010) 1.08
Accurate prediction of drug-induced liver injury using stem cell-derived populations. Stem Cells Transl Med (2013) 1.07
Isolation and culture of primary hepatocytes from resected human liver tissue. Methods Mol Biol (2010) 1.03
Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci (2011) 1.02
SUMOylation of HNF4α regulates protein stability and hepatocyte function. J Cell Sci (2012) 1.01
Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett (1998) 1.01
Laboratory models available to study alcohol-induced organ damage and immune variations: choosing the appropriate model. Alcohol Clin Exp Res (2010) 1.01
Study of hepatocyte differentiation using embryonic stem cells. J Cell Biochem (2005) 1.01
A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping. Hepatology (2000) 0.99
Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening. Toxicology (2010) 0.99
Embryonic stem cell-derived embryoid bodies in three-dimensional culture system form hepatocyte-like cells in vitro and in vivo. Tissue Eng (2005) 0.97
Formation and immunological properties of aldehyde-derived protein adducts following alcohol consumption. Methods Mol Biol (2008) 0.87
In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des (2010) 0.85
Rapid and scalable human stem cell differentiation: now in 3D. Stem Cells Dev (2013) 0.85
A simple and economical route to generate functional hepatocyte-like cells from hESCs and their application in evaluating alcohol induced liver damage. J Cell Biochem (2012) 0.81
Differentiated umbilical cord matrix stem cells as a new in vitro model to study early events during hepatitis B virus infection. Hepatology (2013) 0.80
Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (2012) 10.53
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology (2010) 3.36
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog (2007) 2.98
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology (2005) 2.93
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol (2008) 2.83
Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A (2006) 2.75
Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol (2006) 2.55
Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol (2002) 2.53
Regulation of alternative macrophage activation by galectin-3. J Immunol (2008) 2.28
Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus. RNA (2002) 2.20
Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med (2011) 2.09
DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med (2007) 2.09
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol (2006) 1.99
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology (2006) 1.88
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol (2007) 1.77
Lineage-specific distribution of high levels of genomic 5-hydroxymethylcytosine in mammalian development. Cell Res (2011) 1.76
DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene (2003) 1.76
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J Virol (2008) 1.70
Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol (2006) 1.66
Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol (2008) 1.63
Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol (2010) 1.59
Human DDX3 functions in translation and interacts with the translation initiation factor eIF3. Nucleic Acids Res (2008) 1.57
Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. Hepatology (2008) 1.49
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res (2006) 1.43
Herpes simplex virus type 1 portal protein UL6 interacts with the putative terminase subunits UL15 and UL28. J Virol (2003) 1.37
Progress and future challenges in stem cell-derived liver technologies. Am J Physiol Gastrointest Liver Physiol (2009) 1.32
Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J Gen Virol (2009) 1.30
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol (2007) 1.27
Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl Med (2013) 1.27
Post-translational modification by SUMO. Toxicology (2010) 1.26
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol (2012) 1.24
Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol (2007) 1.24
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
Persistence of functional hepatocyte-like cells in immune-compromised mice. Liver Int (2010) 1.18
Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology (2008) 1.16
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol (2012) 1.12
Analysis of the processing and transmembrane topology of the E2p7 protein of hepatitis C virus. J Gen Virol (2005) 1.12
Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol (2013) 1.11
Pluripotent stem cell-derived hepatocytes: potential and challenges in pharmacology. Annu Rev Pharmacol Toxicol (2013) 1.10
Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS One (2009) 1.10
Identification of herpes simplex virus RNAs that interact specifically with regulatory protein ICP27 in vivo. J Biol Chem (2003) 1.09
The inhibitory role of stromal cell mesenchyme on human embryonic stem cell hepatocyte differentiation is overcome by Wnt3a treatment. Cloning Stem Cells (2008) 1.09
The comparison between conditioned media and serum-free media in human embryonic stem cell culture and differentiation. Cell Reprogram (2010) 1.08
Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins. J Med Virol (2003) 1.08
A conserved proline between domains II and III of hepatitis C virus NS5A influences both RNA replication and virus assembly. J Virol (2009) 1.07
Accurate prediction of drug-induced liver injury using stem cell-derived populations. Stem Cells Transl Med (2013) 1.07
A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res (2009) 1.05
WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer. Mol Biol Cell (2007) 1.05
Cadaveric hepatocytes repopulate diseased livers: life after death. Gastroenterology (2010) 1.05
Amplification and overexpression of the EMS 1 oncogene, a possible prognostic marker, in human hepatocellular carcinoma. J Mol Diagn (2003) 1.05
Liver cell lines for the study of hepatocyte functions and immunological response. Liver Int (2005) 1.02
A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol (2008) 1.02
Expression of DDX3 is directly modulated by hypoxia inducible factor-1 alpha in breast epithelial cells. PLoS One (2011) 1.02
SUMOylation of HNF4α regulates protein stability and hepatocyte function. J Cell Sci (2012) 1.01
Heme oxygenase-1 prevents cardiac dysfunction in streptozotocin-diabetic mice by reducing inflammation, oxidative stress, apoptosis and enhancing autophagy. PLoS One (2013) 1.00
Deriving functional hepatocytes from pluripotent stem cells. Curr Protoc Stem Cell Biol (2014) 0.99
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol (2012) 0.99
Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening. Toxicology (2010) 0.99
Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer. PLoS One (2013) 0.93
Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses (2011) 0.93
Progenitor cell characterization and location in the developing human liver. Stem Cells Dev (2007) 0.91
Liver tissue engineering and cell sources: issues and challenges. Liver Int (2013) 0.91
Characterization of HCV-like particles produced in a human hepatoma cell line by a recombinant baculovirus. Biochem Biophys Res Commun (2005) 0.91
Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes. Mol Med (2006) 0.90
Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell (2010) 0.90
Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. J Gen Virol (2010) 0.89
Expression of hepatitis C virus (HCV) structural proteins in trans facilitates encapsidation and transmission of HCV subgenomic RNA. J Gen Virol (2009) 0.88
Robust generation of hepatocyte-like cells from human embryonic stem cell populations. J Vis Exp (2011) 0.87
Cloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins. Methods Mol Biol (2007) 0.85
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships. J Gen Virol (2011) 0.85
Role of stem-cell-derived hepatic endoderm in human drug discovery. Biochem Soc Trans (2010) 0.84
A genome-wide screen in human embryonic stem cells reveals novel sites of allele-specific histone modification associated with known disease loci. Epigenetics Chromatin (2012) 0.83
Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. Future Microbiol (2011) 0.83
Development of an embryoid body-based screening strategy for assessing the hepatocyte differentiation potential of human embryonic stem cells following single-cell dissociation. Cell Reprogram (2013) 0.83
Three-dimensional culture of human embryonic stem cell derived hepatic endoderm and its role in bioartificial liver construction. J Biomed Biotechnol (2010) 0.83
Non cell autonomous upregulation of CDKN2 transcription linked to progression of chronic hepatitis C disease. Aging Cell (2013) 0.82
Maternal Smoking Dysregulates Protein Expression in Second Trimester Human Fetal Livers in a Sex-Specific Manner. J Clin Endocrinol Metab (2015) 0.82
Protection of hepatocytes from cytotoxic T cell mediated killing by interferon-alpha. PLoS One (2007) 0.81
Hepatic endoderm differentiation from human embryonic stem cells. Curr Stem Cell Res Ther (2010) 0.81
Conserved glycine 33 residue in flexible domain I of hepatitis C virus core protein is critical for virus infectivity. J Virol (2011) 0.81
Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. J Gen Virol (2005) 0.80
Maintaining hepatic stem cell gene expression on biological and synthetic substrata. Biores Open Access (2012) 0.80
Characterisation of bacterially expressed structural protein E2 of hepatitis C virus. Protein Expr Purif (2004) 0.79
Stem cell differentiation and human liver disease. World J Gastroenterol (2012) 0.79
Serum-Free Directed Differentiation of Human Embryonic Stem Cells to Hepatocytes. Methods Mol Biol (2015) 0.79
Novel biopolymers to enhance endothelialisation of intra-vascular devices. Adv Healthc Mater (2012) 0.78